Neospora caninum vaccine
AssigneeThe United States of America as represented by the Secretary of Agriculture
InventorsWenbin Tuo, Mark C. Jenkins, Yan Zhao
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe United States of America as represented by the Secretary of Agriculture
InventorsWenbin Tuo, Mark C. Jenkins, Yan Zhao
Estimating the term…
Neospora caninum is the causal agent of bovine neosporosis which results in high levels of abortion. The protective efficacy of two Neospora antigens: Neospora cyclophilin (NcCyP) and NcSRS2 was evaluated. Mice vaccinated with recombinant (r) NcCyP, rNcSRS2, and the combination rNcCyP plus rNcSRS2, formulated with adjuvant ImmuMax-SR® and CpG were challenge-infected 3 weeks following the booster immunization and necropsied 3 weeks after the challenge infection. Mice vaccinated with rNcCyP, rNcSRS2, or the combination of rNcCyP and rNcSRS2 responded with high levels of NcCyP- or NcSRS2- specific antibodies. Mice which received vaccines formulated with either rNcCyP or the combination rNcCyP and rNcSRS2 had a higher (p<0.01) percent protection when compared to the mock- or non-vaccinated mice. Groups immunized with rNcSRS2 alone exhibited slightly lower levels of protection. Results indicate that NcCyP is a highly efficacious vaccine candidate useful in protection against Neospora infection.
A vaccine comprising an effective amount of an isolated or recombinant Neospora caninum cyclophilin protein (rNcCyP) consisting of the amino acid sequence set forth in SEQ ID NO:
Dependencies are inferred from the claim text.